This research project will serve to reinforce the idea that gene therapy using CRISPR-Cas9 has potential in curing inherited dominant-negative disorders. Previous studies have shown that removal of the transgene in transgenic mice preserves retinal structure and function. Data from this study will go on to prove whether it is feasible to treat CORD6 using virus-mediated gene therapy. Additionally, this study will be used to optimize the various parameters associated with delivering gene therapy treatment in mice, such as time of injection and dosage. I hypothesize that using an Adeno-associated virus encoding a CRISPR-Cas9 complex will slow the progression of the CORD6 diseased state in mice and ultimately stop further photoreceptor death in affected retinas, thus preserving structure and function.